Walgreens Boots Alliance, Inc. (0LSZ.L)
USD 10.22
(-7.23%)
USD 10.22
(-7.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 8.23 Billion USD | -3.88% |
| 2023 | 32.8 Billion USD | -3.85% |
| 2022 | 34.11 Billion USD | 5.96% |
| 2021 | 32.19 Billion USD | -18.74% |
| 2020 | 39.62 Billion USD | 150.58% |
| 2019 | 15.81 Billion USD | 16.17% |
| 2018 | 13.61 Billion USD | 41.29% |
| 2017 | 9.63 Billion USD | 4.48% |
| 2016 | 9.22 Billion USD | -18.99% |
| 2015 | 11.38 Billion USD | 510.68% |
| 2014 | 1.86 Billion USD | -36.62% |
| 2013 | 2.94 Billion USD | -28.18% |
| 2012 | 4.09 Billion USD | 380.07% |
| 2011 | 853 Million USD | 63.72% |
| 2010 | 521 Million USD | 97.35% |
| 2009 | 264 Million USD | -72.98% |
| 2008 | 977.2 Million USD | 56.68% |
| 2007 | 623.7 Million USD | 167.8% |
| 2006 | -919.9 Million USD | -59.48% |
| 2005 | -576.8 Million USD | 65.98% |
| 2004 | -1.69 Billion USD | -66.7% |
| 2003 | -1.01 Billion USD | -126.07% |
| 2002 | -449.9 Million USD | -206.16% |
| 2001 | 423.8 Million USD | 3410.94% |
| 2000 | -12.8 Million USD | 90.97% |
| 1999 | -141.8 Million USD | 1.53% |
| 1998 | -144 Million USD | -97.26% |
| 1997 | -73 Million USD | -729.55% |
| 1996 | -8.8 Million USD | 60.36% |
| 1995 | -22.2 Million USD | 71.5% |
| 1994 | -77.9 Million USD | 14.96% |
| 1993 | -91.6 Million USD | 24.67% |
| 1992 | -121.6 Million USD | -320.29% |
| 1991 | 55.2 Million USD | 186.25% |
| 1990 | -64 Million USD | 11.72% |
| 1989 | -72.5 Million USD | -115.77% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 32.96 Billion USD | -2.94% |
| 2024 Q1 | 32.95 Billion USD | 0.45% |
| 2024 Q4 | 8.23 Billion USD | -4.33% |
| 2024 Q2 | 33.95 Billion USD | 3.05% |
| 2023 Q2 | 36.48 Billion USD | 10.03% |
| 2023 FY | 32.8 Billion USD | -3.85% |
| 2023 Q1 | 33.16 Billion USD | -2.8% |
| 2023 Q3 | 35.56 Billion USD | -2.52% |
| 2023 Q4 | 32.8 Billion USD | -7.77% |
| 2022 FY | 34.11 Billion USD | 5.96% |
| 2022 Q4 | 34.11 Billion USD | -2.49% |
| 2022 Q2 | 35.65 Billion USD | 4.61% |
| 2022 Q1 | 34.08 Billion USD | 5.84% |
| 2022 Q3 | 34.99 Billion USD | -1.85% |
| 2021 Q3 | 38.76 Billion USD | -2.17% |
| 2021 Q4 | 32.19 Billion USD | -16.94% |
| 2021 Q1 | 39.7 Billion USD | 0.21% |
| 2021 Q2 | 39.62 Billion USD | -0.21% |
| 2021 FY | 32.19 Billion USD | -18.74% |
| 2020 FY | 39.62 Billion USD | 150.58% |
| 2020 Q1 | 40.22 Billion USD | 154.37% |
| 2020 Q2 | 40.05 Billion USD | -0.42% |
| 2020 Q3 | 39.95 Billion USD | -0.25% |
| 2020 Q4 | 39.62 Billion USD | -0.83% |
| 2019 FY | 15.81 Billion USD | 16.17% |
| 2019 Q3 | 16.77 Billion USD | -2.63% |
| 2019 Q4 | 15.81 Billion USD | -5.71% |
| 2019 Q2 | 17.22 Billion USD | 14.74% |
| 2019 Q1 | 15.01 Billion USD | 10.27% |
| 2018 FY | 13.61 Billion USD | 41.29% |
| 2018 Q1 | 12.17 Billion USD | 26.38% |
| 2018 Q2 | 13.92 Billion USD | 14.36% |
| 2018 Q3 | 13.22 Billion USD | -5.01% |
| 2018 Q4 | 13.61 Billion USD | 2.93% |
| 2017 Q1 | 9.27 Billion USD | 0.57% |
| 2017 FY | 9.63 Billion USD | 4.48% |
| 2017 Q4 | 9.63 Billion USD | 38.48% |
| 2017 Q3 | 6.95 Billion USD | -1.86% |
| 2017 Q2 | 7.08 Billion USD | -23.56% |
| 2016 Q3 | 10.23 Billion USD | -1.97% |
| 2016 Q2 | 10.44 Billion USD | -10.82% |
| 2016 FY | 9.22 Billion USD | -18.99% |
| 2016 Q4 | 9.22 Billion USD | -9.9% |
| 2016 Q1 | 11.7 Billion USD | 2.85% |
| 2015 Q4 | 11.38 Billion USD | -3.52% |
| 2015 Q2 | 14.05 Billion USD | 742.24% |
| 2015 Q1 | 1.66 Billion USD | -10.46% |
| 2015 FY | 11.38 Billion USD | 510.68% |
| 2015 Q3 | 11.79 Billion USD | -16.07% |
| 2014 Q1 | 4.1 Billion USD | 39.51% |
| 2014 Q4 | 1.86 Billion USD | -22.37% |
| 2014 Q3 | 2.4 Billion USD | -27.0% |
| 2014 Q2 | 3.28 Billion USD | -19.84% |
| 2014 FY | 1.86 Billion USD | -36.62% |
| 2013 FY | 2.94 Billion USD | -28.18% |
| 2013 Q4 | 2.94 Billion USD | -12.78% |
| 2013 Q3 | 3.37 Billion USD | -14.11% |
| 2013 Q2 | 3.92 Billion USD | -13.83% |
| 2013 Q1 | 4.55 Billion USD | 11.26% |
| 2012 Q1 | 1.3 Billion USD | 53.22% |
| 2012 FY | 4.09 Billion USD | 380.07% |
| 2012 Q4 | 4.09 Billion USD | 911.11% |
| 2012 Q3 | 405 Million USD | -69.06% |
| 2012 Q2 | 1.3 Billion USD | 0.15% |
| 2011 Q3 | -257 Million USD | -271.33% |
| 2011 Q4 | 853 Million USD | 431.91% |
| 2011 Q1 | 340 Million USD | -34.74% |
| 2011 Q2 | 150 Million USD | -55.88% |
| 2011 FY | 853 Million USD | 63.72% |
| 2010 Q2 | -146 Million USD | 15.61% |
| 2010 FY | 521 Million USD | 97.35% |
| 2010 Q1 | -173 Million USD | -165.53% |
| 2010 Q4 | 521 Million USD | -20.58% |
| 2010 Q3 | 656 Million USD | 549.32% |
| 2009 Q4 | 264 Million USD | 450.0% |
| 2009 FY | 264 Million USD | -72.98% |
| 2009 Q1 | 1.53 Billion USD | 56.67% |
| 2009 Q2 | 1.43 Billion USD | -6.27% |
| 2009 Q3 | 48 Million USD | -96.66% |
| 2008 Q2 | 472.5 Million USD | -45.78% |
| 2008 FY | 977.2 Million USD | 56.68% |
| 2008 Q1 | 871.4 Million USD | 39.71% |
| 2008 Q3 | 664.5 Million USD | 40.63% |
| 2008 Q4 | 977.2 Million USD | 47.06% |
| 2007 Q1 | -669.7 Million USD | 27.2% |
| 2007 Q2 | -694.2 Million USD | -3.66% |
| 2007 Q3 | -567.4 Million USD | 18.27% |
| 2007 Q4 | 623.7 Million USD | 209.92% |
| 2007 FY | 623.7 Million USD | 167.8% |
| 2006 Q1 | -584.1 Million USD | -1.27% |
| 2006 Q3 | -802.4 Million USD | -38.63% |
| 2006 Q4 | -919.9 Million USD | -14.64% |
| 2006 FY | -919.9 Million USD | -59.48% |
| 2006 Q2 | -578.8 Million USD | 0.91% |
| 2005 Q4 | -576.8 Million USD | -6.58% |
| 2005 FY | -576.8 Million USD | 65.98% |
| 2005 Q3 | -541.2 Million USD | -19.44% |
| 2005 Q2 | -453.1 Million USD | 65.5% |
| 2005 Q1 | -1.31 Billion USD | 22.54% |
| 2004 Q1 | -868.1 Million USD | 14.65% |
| 2004 Q2 | -1.1 Billion USD | -27.54% |
| 2004 Q3 | -1.57 Billion USD | -42.43% |
| 2004 FY | -1.69 Billion USD | -66.7% |
| 2004 Q4 | -1.69 Billion USD | -7.51% |
| 2003 Q3 | -854.4 Million USD | -25.06% |
| 2003 Q2 | -683.2 Million USD | -132.14% |
| 2003 FY | -1.01 Billion USD | -126.07% |
| 2003 Q1 | -294.3 Million USD | 34.59% |
| 2003 Q4 | -1.01 Billion USD | -19.04% |
| 2002 FY | -449.9 Million USD | -206.16% |
| 2002 Q3 | -286.2 Million USD | -424.12% |
| 2002 Q4 | -449.9 Million USD | -57.2% |
| 2002 Q1 | 654.7 Million USD | 54.48% |
| 2002 Q2 | 88.3 Million USD | -86.51% |
| 2001 Q4 | 423.8 Million USD | 63.57% |
| 2001 Q3 | 259.1 Million USD | 3.56% |
| 2001 Q2 | 250.2 Million USD | -44.03% |
| 2001 FY | 423.8 Million USD | 3410.94% |
| 2001 Q1 | 447 Million USD | 3592.19% |
| 2000 Q1 | 86 Million USD | 160.65% |
| 2000 Q2 | -4.7 Million USD | -105.47% |
| 2000 Q3 | -47 Million USD | -900.0% |
| 2000 FY | -12.8 Million USD | 90.97% |
| 2000 Q4 | -12.8 Million USD | 72.77% |
| 1999 Q4 | -141.8 Million USD | 44.46% |
| 1999 Q1 | -13 Million USD | 90.97% |
| 1999 FY | -141.8 Million USD | 1.53% |
| 1999 Q2 | -263.6 Million USD | -1927.69% |
| 1999 Q3 | -255.3 Million USD | 3.15% |
| 1998 FY | -144 Million USD | -97.26% |
| 1998 Q1 | 21 Million USD | 128.77% |
| 1998 Q2 | -35 Million USD | -266.67% |
| 1998 Q3 | -111 Million USD | -217.14% |
| 1998 Q4 | -144 Million USD | -29.73% |
| 1997 Q1 | 11.9 Million USD | 235.23% |
| 1997 Q2 | -20.9 Million USD | -275.63% |
| 1997 Q3 | -137.7 Million USD | -558.85% |
| 1997 Q4 | -73 Million USD | 46.99% |
| 1997 FY | -73 Million USD | -729.55% |
| 1996 Q4 | -8.8 Million USD | 81.7% |
| 1996 Q2 | -7.8 Million USD | -111.19% |
| 1996 Q1 | 69.7 Million USD | 413.96% |
| 1996 FY | -8.8 Million USD | 60.36% |
| 1996 Q3 | -48.1 Million USD | -516.67% |
| 1995 Q1 | 18.8 Million USD | 124.13% |
| 1995 Q3 | -116 Million USD | -117.23% |
| 1995 Q2 | -53.4 Million USD | -384.04% |
| 1995 Q4 | -22.2 Million USD | 80.86% |
| 1995 FY | -22.2 Million USD | 71.5% |
| 1994 Q2 | -48.5 Million USD | -432.97% |
| 1994 Q4 | -77.9 Million USD | 56.7% |
| 1994 Q3 | -179.9 Million USD | -270.93% |
| 1994 FY | -77.9 Million USD | 14.96% |
| 1994 Q1 | -9.1 Million USD | 90.07% |
| 1993 Q1 | 23.9 Million USD | 119.65% |
| 1993 Q4 | -91.6 Million USD | 46.37% |
| 1993 Q3 | -170.8 Million USD | -370.52% |
| 1993 FY | -91.6 Million USD | 24.67% |
| 1993 Q2 | -36.3 Million USD | -251.88% |
| 1992 FY | -121.6 Million USD | -320.29% |
| 1992 Q1 | 64 Million USD | 15.94% |
| 1992 Q2 | -38.2 Million USD | -159.69% |
| 1992 Q3 | -51.9 Million USD | -35.86% |
| 1992 Q4 | -121.6 Million USD | -134.3% |
| 1991 Q3 | -65.6 Million USD | 15.35% |
| 1991 Q1 | -11.1 Million USD | 82.66% |
| 1991 FY | 55.2 Million USD | 186.25% |
| 1991 Q2 | -77.5 Million USD | -598.2% |
| 1991 Q4 | 55.2 Million USD | 184.15% |
| 1990 Q4 | -64 Million USD | 32.42% |
| 1990 FY | -64 Million USD | 11.72% |
| 1990 Q3 | -94.7 Million USD | -5.46% |
| 1990 Q2 | -89.8 Million USD | -195.39% |
| 1990 Q1 | -30.4 Million USD | 58.07% |
| 1989 FY | -72.5 Million USD | -115.77% |
| 1989 Q4 | -72.5 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 8098.951% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 26479.857% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -4057.726% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -25727.191% |
| bluebird bio, Inc. | 108.57 Million USD | -7484.898% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 91437.622% |
| Imunon, Inc. | -4.69 Million USD | 175339.872% |
| Editas Medicine, Inc. | -87.11 Million USD | 9552.913% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 35.939% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | -292.524% |
| Myriad Genetics, Inc. | 88.1 Million USD | -9247.333% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -4544.67% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 24662.293% |
| Verastem, Inc. | -37.27 Million USD | 22190.777% |
| Waters Corporation | 1.96 Billion USD | -320.059% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 69.318% |
| Biogen Inc. | 6.28 Billion USD | -30.957% |
| Nektar Therapeutics | 210.24 Million USD | -3816.952% |
| Perrigo Company plc | 3.32 Billion USD | -147.885% |
| Dynavax Technologies Corporation | 106.63 Million USD | -7622.605% |
| Illumina, Inc. | 1.21 Billion USD | -578.336% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -118081.834% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 7330.788% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -5576.335% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -114481.884% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -2074.269% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 116085.915% |
| Evolus, Inc. | 63.7 Million USD | -12826.163% |
| Adicet Bio, Inc. | -142 Million USD | 5898.969% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 22475.285% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 30487.454% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -1695.295% |
| FibroGen, Inc. | 56.76 Million USD | -14406.668% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -619.214% |
| OPKO Health, Inc. | 230.68 Million USD | -3469.834% |
| Homology Medicines, Inc. | 18.43 Million USD | -44565.618% |
| Geron Corporation | 14.76 Million USD | -55688.903% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | -419.451% |
| Exelixis, Inc. | -73.05 Million USD | 11373.101% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 15278.045% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 5552.776% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 7492.147% |
| Zoetis Inc. | 4.76 Billion USD | -72.932% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 4221.188% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 81869.437% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 186.105% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 56612.49% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -681.107% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -750.391% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 6181.979% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -496.36% |
| Blueprint Medicines Corporation | 702.83 Million USD | -1071.682% |
| Insmed Incorporated | 721.62 Million USD | -1041.182% |
| TG Therapeutics, Inc. | 17.86 Million USD | -46003.46% |
| Incyte Corporation | -3.17 Billion USD | 359.363% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -975.346% |